SCHEMBL2999233

SCHEMBL2999233

O=S(=O)(c1cccc(Cl)c1Cl)N1CCN(c2nc(Cc3cc(F)cc(Cl)c3)cs2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.45
KMT2A Q03164 4/20 0.45
MAPT P10636 4/20 0.45
LMNA P02545 4/20 0.45
ALDH1A1 P00352 3/20 0.45
MEN1 O00255 2/20 0.45
TSHR P16473 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
USP2 O75604 1/20 0.39
RECQL P46063 1/20 0.39
HSD17B10 Q99714 1/20 0.39
POLB P06746 3/20 0.38
KDM4E B2RXH2 2/20 0.38
RAB9A P51151 1/20 0.37
PKM P14618 2/20 0.37
GAA P10253 1/20 0.37
MAPK1 P28482 3/20 0.36
CHRM1 P11229 1/20 0.36
HTR6 P50406 1/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017663 0.95 KMT2A (0.47) SMN1; SMN2KMT2AMAPTLMNAALDH1A1
SCHEMBL3007745 0.93 TSHR (0.44) SMN1; SMN2KMT2AMAPTLMNAALDH1A1
SCHEMBL3020813 0.93 KMT2A (0.46) SMN1; SMN2KMT2AMAPTLMNAALDH1A1
SCHEMBL3012907 0.88 SMN1; SMN2 (0.44) SMN1; SMN2KMT2AMAPTLMNAALDH1A1
SCHEMBL3015125 0.88 LMNA (0.44) SMN1; SMN2KMT2AMAPTLMNAALDH1A1
SCHEMBL3016580 0.88 KMT2A (0.44) SMN1; SMN2KMT2AMAPTLMNAALDH1A1
SCHEMBL3018664 0.88 KMT2A (0.48) SMN1; SMN2KMT2AMAPTLMNAALDH1A1
SCHEMBL3006130 0.87 ALDH1A1 (0.43) SMN1; SMN2KMT2AMAPTLMNAALDH1A1
SCHEMBL2998179 0.87 ALDH1A1 (0.43) SMN1; SMN2KMT2AMAPTLMNAALDH1A1
SCHEMBL3012169 0.87 PKM (0.43) SMN1; SMN2KMT2AMAPTLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885KMT2A 2680/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.